Regulatory tracker
Where each compound stands
33 prescription and experimental compounds, grouped by regulatory status. Each entry carries the reasoning, the sources, and the date it was last verified. This is a moving target — the dates matter.
Most recent verification: 27 August 2026
Approved
16- ACE Inhibitor or ARB
Class-level: multiple FDA-approved antihypertensives (Rx).
Verified 27 August 2026 - Bempedoic Acid
Approved (Nexletol), Rx.
Verified 27 August 2026 - Dasatinib + Quercetin
Components: dasatinib approved (oncology, Rx); quercetin lawful supplement. The senolytic protocol itself is off-label/investigational use of an approved drug.
Verified 27 August 2026 - Ezetimibe
Approved (Zetia), Rx.
Verified 27 August 2026 - GLP-1 Receptor Agonist
Class doc: semaglutide/tirzepatide/liraglutide approved (Rx). Compounded copies barred outside narrow documented clinical need post-shortage; proposed 503B exclusion pending, not final.
Sources: newdrugloft.com (opens in a new tab)iapam.com (opens in a new tab)
Verified 27 August 2026 - Hair Loss Treatment
Class-level: finasteride (Rx), minoxidil (OTC) approved.
Verified 27 August 2026 - Menopausal Hormone Therapy
Class-level: multiple approved products (Rx).
Verified 27 August 2026 - Metformin
Approved (Rx); longevity use is off-label.
Verified 27 August 2026 - PCSK9 Inhibitor
Class: approved (Rx).
Verified 27 August 2026 - Rapamycin
Approved as sirolimus (Rapamune), Rx; longevity dosing is off-label.
Verified 27 August 2026 - SGLT2 Inhibitor
Class: approved (Rx).
Verified 27 August 2026 - SS-31 (Elamipretide)
Accelerated approval Sept 19 2025 as Forzinity (elamipretide HCl) for Barth syndrome (patients ≥30 kg) — first approved mitochondria-targeted therapeutic; ultra-rare indication (~150 US patients); longevity/wellness use is off-label with no practical access channel; RUO product remains unlawful.
Verified 27 August 2026 - Statins
Class: approved (Rx).
Verified 27 August 2026 - Tesamorelin
Approved (Egrifta), HIV-associated lipodystrophy; off-label prescribing is physician discretion.
Sources: 1stoptimal.com (opens in a new tab)
Verified 27 August 2026 - Testosterone Replacement (Clinical)
Approved (Rx); Schedule III controlled substance — additional prescribing rules apply.
Verified 27 August 2026 - Topical Retinoid
Class: tretinoin (Rx), adapalene (OTC) approved.
Verified 27 August 2026
Compoundable
1- Sermorelin
No approved product currently marketed; available via 503A compounding; 1997 approval discontinued for business, not safety, reasons.
Sources: karpahealth.com (opens in a new tab)peptidedossier.com (opens in a new tab)
Verified 27 August 2026
Investigational
1- Retatrutide
Phase 3 (TRIUMPH); FDA explicit: cannot be used in compounding under federal law; NDA expected late 2026/early 2027, approval projected 2027-28; Lilly expanded-access program formalized Aug 3 2026 (narrow, physician-applied). Only lawful routes: trial or expanded access.
Sources: scriptlinkrx.com (opens in a new tab)middlewaynutrition.com (opens in a new tab)
Verified 27 August 2026
Gray zone
12- BPC-157
Removed from Category 2 Apr 2026; PCAC recommended 8-6 Jul 23 2026; compounding remains unlawful pending rulemaking (est. 12-24 mo).
Sources: bipc.com (opens in a new tab)ajmc.com (opens in a new tab)techtimes.com (opens in a new tab)
Verified 27 August 2026 - CJC-1295
Removed from Category 2 Apr 2026 but not moved to Category 1; no lawful channel currently.
Sources: newdrugloft.com (opens in a new tab)
Verified 27 August 2026 - GHK-Cu
Doc covers both topical (cosmetic) and systemic/injectable use with therapeutic tissue-repair/wound-healing claims. otc_lawful applies only to cosmetic-claim topical use; the therapeutic claims and systemic/injectable scope place it in gray_zone — on the announced ~Feb 2027 PCAC agenda; injectable form historically on the FDA safety-risk list; trackers conflict.
Sources: restorativecompounding.com (opens in a new tab)nationwidecompounding.com (opens in a new tab)iapam.com (opens in a new tab)
Verified 27 August 2026 - Hexarelin
Not approved; no lawful human-use channel; conflicting secondary reports on inclusion in the reclassification wave; WADA-prohibited.
Sources: riteaid.com (opens in a new tab)
Verified 27 August 2026 - Humanin
Research-stage endogenous mitochondrial peptide; no approved product, no compounding pathway, no active regulatory proceedings. Verification basis: absence from approval/compounding records as of 2026-08-27.
Verified 27 August 2026 - Ipamorelin
Active litigation; trackers report currently prohibited pending court outcome — treat as unavailable via licensed channels.
Verified 27 August 2026 - KPV
PCAC recommended 8-6 Jul 2026; unlawful pending rulemaking.
Sources: bipc.com (opens in a new tab)ajmc.com (opens in a new tab)
Verified 27 August 2026 - MK-677 (Ibutamoren)
Never FDA-approved (Merck program discontinued; no NDA filed); cannot lawfully be sold as a dietary supplement (investigational-first preclusion; FDA warning letters incl. Dec 2025); not DEA-scheduled; trackers conflict on compounding eligibility; WADA-prohibited.
Sources: peptidemark.com (opens in a new tab)telehealthally.com (opens in a new tab)legalclarity.org (opens in a new tab)
Verified 27 August 2026 - MOTS-c
PCAC recommended 7-5 Jul 2026; unlawful pending rulemaking.
Sources: bipc.com (opens in a new tab)ajmc.com (opens in a new tab)
Verified 27 August 2026 - TB-500
Removed from Category 2 Apr 2026; PCAC recommended 8-6 Jul 23 2026; unlawful pending rulemaking.
Sources: bipc.com (opens in a new tab)ajmc.com (opens in a new tab)
Verified 27 August 2026 - Thymalin
Not FDA-approved (no NDA/IND on record); no compounding pathway; named by compound in a Feb 2024 FDA warning letter as an unapproved new drug; Russian approval has no US bearing.
Sources: riteaid.com (opens in a new tab)peptidesexplorer.com (opens in a new tab)
Verified 27 August 2026 - Thymosin Alpha-1
Never FDA-approved — prescribing it is prescribing an unapproved drug, not off-label use; ex-US approvals (Zadaxin) have no US bearing; sources conflict (some programs list it; Jul 2026 tracker reports active litigation/prohibited).
Sources: karpahealth.com (opens in a new tab)peptidedossier.com (opens in a new tab)nationwidecompounding.com (opens in a new tab)mypeptidematch.com (opens in a new tab)
Verified 27 August 2026
Prohibited
3- DSIP (Emideltide)
PCAC voted against inclusion 6-7 on Jul 24 2026.
Sources: bipc.com (opens in a new tab)ajmc.com (opens in a new tab)
Verified 27 August 2026 - GHRP-2
Category 2; conflicting secondary reports on reclassification intent.
Sources: peptide-db.com (opens in a new tab)
Verified 27 August 2026 - Verified 27 August 2026